<DOC>
	<DOCNO>NCT02614339</DOCNO>
	<brief_summary>The aim study identify effect adjunctive metformin recurrence non-DM stage III colorectal cancer . This study open-label randomize control study . The primary endpoint compare 3-year disease free survival metformin group non-metformin group . The secondary endpoint compare 5-year overall survival disease specific survival two group , identify safety metformin , compare recurrence rate polyp polypectomy two group .</brief_summary>
	<brief_title>Effect Adjunctive Metformin Recurrence Non-DM Stage III Colorectal Cancer : Open-label Randomized Controlled Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1. patient stage III colorectal cancer take operation cure , patient stage III rectal cancer take chemoradiation therapy subsequently operation 2. age 20 80 year 3. patient without DM 4. patient well performance status chemotherapy 5. patient agree study protocol 1. patient DM 2. patient diagnosed cancer ( ≥ stage II ) within 5 year 3. patient familial adenomatous polyposis , hereditary nonpolyposis colorectal cancer , inflammatory bowel disease 4. patient take chemoprevention drug ( ex . NSAIDs , Aspirin ) 5. patient risk factor increase lactic acidosis renal disease , lung disease , liver disease , infectious disease 6 . Creatinine ≥ 1.5mg/dL ( male ) , ≥ 1.4mg/dL ( female ) 7. patient congestive heart failure need treat 8. patient allergic history metformin 9. pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>